Company intelligence / Profile preview

NEC OncoImmunity

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

NEC OncoImmunity’s technology has demonstrated that high-quality neoantigen prediction correlates with improved progression-free survival in sarcoma patients treated with checkpoint inhibitors. Clinical trials are ongoing for personalized cancer vaccines such as TG4050 targeting ovarian and head & neck cancers. The company also develops broadly protective vaccine designs against infectious diseases using its AI platform

Therapeutic areas: OncologyInfectious Diseases
Modalities: Personalized cancer vaccinesAI-designed peptide vaccinesimmunotherapies
Industry: Biotech

Drug pipeline

1 asset

VXM NEO

Unknown

Partnerships

Transgene SA—collaboration on TG4050 personalized immunotherapy clinical trialsCEPI—collaboration/funding for broadly protective coronavirus vaccines developmentNagasaki University—research collaboration on tropical diseases funded by SCARDABostonGene—strategic investment partnership focused on advanced patient analysis for optimal therapy selection

Beyond the preview

Go deeper on NEC OncoImmunity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEC OncoImmunity.

Explore the full profile